期刊文献+

中剂量rhG-CSF动员对供者外周血免疫细胞组成的影响 被引量:6

Effects of Mobilization with Medium Dose of rhG-CSF on the Immunocyte Component of Peripheral Blood in Donors
下载PDF
导出
摘要 本研究观察12例健康供者在使用10μg/(kg·day)rhGCSF动员前后白细胞总数变化。应用外周血涂片瑞氏染色对白细胞进行形态学分类,使用流式细胞术分析动员前后外周血单个核细胞中T细胞、B细胞、NK细胞和单核细胞比例的变化。结果发现,动员前1天外周血白细胞计数中位数为6.25(4.7-7.8)×109/L,其中淋巴细胞中位数为2.07(1.63-3.1)×109/L,单核细胞中位数为0.163(0.078-0.414)×109/L;动员第5天外周血白细胞计数中位数为37.47(24-72.57)×109/L,其中淋巴细胞中位数为3.22(1.46-5.31)×109/L,单核细胞中位数为1.2(0.706-3.627)×109/L。供者外周血白细胞的增加为动员前的6.26±2.14倍(P<0.01),其中淋巴细胞的增加为动员前的1.45±0.76倍(P<0.05),单核细胞数增加为动员前的7.48±4.41倍(P<0.01)。流式细胞术分析发现,动员前CD3+T淋巴细胞占外周血单个核细胞(PBMNC)比例的中位数为46.96%[(32.36-57.45)%],动员后为40.94%[(25.31-48.9)%];动员前CD4+/CD8+淋巴细胞比例为1.27±0.46,动员后为1.36±0.51;动员前CD4+CD8+T淋巴细胞占PBMNC比例的中位数为0.41%[(0.16-1.51)%],动员后为0.49%[(0.09-2.0)%];动员前CD16+CD56+NK细胞占PBMNC比例的中位数为13.98%[(4.08-25.08)%],动员后为16.65%[(12.06-33.05)%];动员前CD3+CD16+CD56+NK-T细胞占PBMNC比例的中位数为2.75%[(0.37-6.38)%],动员后为3.13%[(0.46-5.95)%];动员前CD20+B淋巴细胞占PBMNC比例的中位数为9.28%[(5.97-16.33)%],动员后为9.94%[(7.36-20.41)%];动员前CD14+单核细胞占PBMNC比例的中位数为12.48%[(3.54-19.35)%],动员后为29.52%[(16.51-36.76)%]。动员后CD14+单核细胞在PBMNC中的比例比动员前增加2.87±1.51倍(P<0.05);动员前后T淋巴细胞、NK细胞、NK-T细胞、B淋巴细胞在PBMNC中的比例以及动员前后CD4+/CD8+淋巴细胞比均无显著变化(P>0.10)。结论:rhGCSF动员引起的单核细胞增加可能在异基因外周血造血干/祖细胞移植的相关事件中发挥着重要作用。 To investigate the changes of donorg peripheral blood immunocytes after mobilization with medium - dose recombinant human granulocyte -colony stimulating factor( rhG-CSF), the amounts of immunocytes in peripheral blood cells and the immunocyte components of donor peripheral blood mononuclear cells(PBMNC) in 12 healthy donors were detected by flow cytometry before and after mobilization with rhG-CSF 10 μg/( kg·day). The results showed that the median amounts of peripheral blood leukocytes before mobilization was 6.25 (4.7 -7.8 )×10^9/L, for lymphocytes it was 2.07 (1.63 -3.10)×10^9/L, and for monocytes it was 0. 163 (0,078 -0.414)×10^9/L. In the fifth day after mobilization, the median amounts of peripheral blood leukocytes was 37.47 (24 -72.57 )×10^9/L, and for lymphocytes it was 3.22 ( 1. 46 -5.31)×10^9/L, and for monocytes, it was 1.2 (0. 706 -3. 627 )×10^9/L. The average amount of leukocytes after mobilization was 6.26 ±2.14 multiple of that before mobilization( P 〈0.01) ,and the median amounts of lymphocytes after mobilization was 1.45 ± 0.76 multiple of that before mobilization ( P 〈 0.05 ), and the amount of monocytes after mobilization was 7.48 ± 4.41 multiple of that before mobilization ( P 〈 0.01 ). The median percentage of CD3^+ T lymphocytes before mobilization was 46.96% [ ( 32.36 - 57.45 ) % ] , but 40.94% [ ( 25.31 - 48.9 ) % ] after mobilization. The ratio of CD4^+/CD8^+ before mobilization was 1.27 ± 0.46, while 1.36 ± 0.51 after mobilization. The median percentage of CD4^+CD8^+T lymphocytes was 0.41% [ (0. 16 - 1. 51 )% ] , and 0. 49% [ (0.09 - 2.0) % ] after mobilization. The median percentage of CD16 ^+ CD56 ^+NK cells was 13.98% [ ( 4.08 - 25.08 ) % ] vevsus 16.65% [ ( 12.06 - 33.05 ) % ] after mobilization. The median percentage of CD3^+ CD16^+ CD56^+ NK-T cells was 2.75 % [ (0.37 - 6.38 ) % ] , but 3.13 % [( 0.46 - 5.95 ) % ] after mobilization. The median percentage of CD20^+ B cells was 9.28% [( 5.97 - 16.33 ) % ] , while 9.94% [ (7.36 - 20.41 ) % ] after mobilization. The median percentage of CD14^+ monocytes was 12.48% [ ( 3.54 - 19.35 ) % ] vevsus 29.52% [ ( 16.51 - 36.76 ) % ] after mobilization. The percentage of CD3^+ T lymphocytes, CD4^+ CD8^+ T lymphocytes, NK cells, NK-T cells and B lymphocytes in PBMNC did not change markedly before and after mobilization with middle-dose rhG-CSF. The ratio of CD4^+/CD8^+ did not change significantly (P 〉 0. 10). The percentages of CD14^+ monocytes in PBMNC after mobiliztion increased up to 2.87 ± 1.51 higher than that before mobilization (P 〈0.05). It is concluded that the changes of the CD14^+ monocytes aftermobilization with rhG-CSF may be involved in graft rejection and graft versus host disease after allo-PBSCT.
出处 《中国实验血液学杂志》 CAS CSCD 2005年第5期852-856,共5页 Journal of Experimental Hematology
基金 解放军总医院十五科研计划基金重点资助项目 编号01YZ05
关键词 重组人粒细胞集落刺激因子 动员 免疫细胞 外周血 recombinant human granulocyte-colony stimulating factor mobilization immunocyte peripheral blood
  • 相关文献

参考文献7

  • 1Koc ON , Gerson SL , Phillips GL, et al. Autologous CD34 + cell transplantation for patients with advanced lymphoma: effects of overnight storage on peripheral blood progenitor cell enrichment and engraftment. Bone Marrow Transplant, 1998; 21:337 -343.
  • 2达万明,黄文荣.异基因外周血造血干/祖细胞移植的进展[J].临床血液学杂志,2003,16(3):144-147. 被引量:12
  • 3Clark L, Clark O, Djulbegovic B, et al. Allogeneic peripheral blood stem cells vs. bone marrow transplantation for the therapy of hematological malignancies: a meta - analysis of randomized controlled trials. Blood, 2001; 98: 414.
  • 4Rutella S, Rumi C, Testa U, et al. Inhibition of lymphocyte blastogenic response in healthy donors treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF): possible role of lactoferrin and interleukin-1 receptor antagonist. Bone Marrow Transplant, 1997; 20:355-364.
  • 5Saito M, Kiyokawa N, Taguchi T, et al. Granulocyte colony-stimulating factor directly affects human monocytes and modulates cytokine secretion. Exp Hematol, 2002; 30: 1115 - 1123.
  • 6Mielcarek M, Graf L, Johnson G, et al. Production of interleukin10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. Blood, 1998; 92: 215 - 222.
  • 7Joss A, Akdis M, Faith A, et al. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol, 2000; 30:1683-1690.

二级参考文献14

  • 1Anderlini P, Rizzo J D, Nugent M L, et al. Peripheral blood stem cell donation: an analysis from the international bone marrow transplant registry (IBMTR) and european group for blood and marrow transplant (EB-MT) databases. Bone Marrow Transplantation, 2001,27: 689-- 692.
  • 2Brasel K, McKenna H J, Charrier K, et al. Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice.Blood,1997,90:3781-3788.
  • 3Anderlini P, Przepiorka D, Korbling M, et al. Blood stem cell procurement: donor safety issues. Bone Marrow Transplantation, 1998, 21(Suppl) :3S35--39.
  • 4Anderlini P, Korbling M. The use of mobilized peripheral blood stem cells from normal donors for allografting. Stem-Cells, 1997, 15: 9--17.
  • 5Anderlini P, Korbling M, Chan K W,et al. Long-term follow-up and safety of normal peripheral blood progenitor cell donors treated with filgrastim: the MD anderson cancer center experience [abstract]. Blood, 2001, 98:183--187.
  • 6Theilgaard M K, Raaschou J K, Andersen H, et al.Single leukapheresis products collected from healthy donors after the administration of granulocyte colony-stimulating factor contain ten-fold higher numbers of longterm reconstituting hematopoietic progenitor cells than conventional bone marrow allografts. Bone-MarrowTransnlant, 1999, 23: 243--249.
  • 7Hoef M V. HLA-identical sibling peripheral blood progenitor cell transplants (PBPCT). Bone Marrow Transplant, 1999. 24: 707--714.
  • 8Ottiger H D. Scheulen B. Beelen D W, et al. Immune reconstitution after allogeneic peripheral blood progenitor cell transplantation [abstract]. Bone marrow transplantation, 1996, 17 (Supp12):135--139.
  • 9Clark L, Clark O, Djulbegovic B, et al. Allogeneic peripheral blood stem cells vs bone marrow transplantation for the therapy of hematological malignancies: a meta-analysis of randomized controlled trials [abstract].Blood, 2001, 98:414--417.
  • 10Bensinger W I, Clift R, Martin P, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced malignancies:a retrospective comparison with marrow transplantation. Blood, 1996, 88:2794-- 2800.

共引文献11

同被引文献62

  • 1黄晓军,陈育红,许兰平,张耀臣,刘代红,郭乃榄,陆道培.G-CSF动员的骨髓及外周血干细胞移植治疗重型再生障碍性贫血[J].基础医学与临床,2004,24(3):291-294. 被引量:13
  • 2肖秀斌,郭梅,乔建辉,王丹红,孙琪云,艾辉胜.单次和分次应用G-CSF动员供体外周血造血干细胞的效果比较[J].解放军医学杂志,2004,29(7):603-604. 被引量:5
  • 3黄文荣,达万明.rhG-CSF在动员外周血造血干/祖细胞过程中对T细胞的影响及机制[J].中国实验血液学杂志,2005,13(2):338-342. 被引量:11
  • 4黄文荣,王立生,高春记,鲁茁壮,王华,段海峰,达万明.rhG-CSF动员对供者T细胞增殖和细胞毒的影响[J].中国实验血液学杂志,2006,14(5):995-998. 被引量:3
  • 5Saito M, Kiyokawa N, Taguchi T,et al. Granulocyte colony -stimulating factor directly affects human monocytes and modulates cytokine secretion. Exp Hematol, 2002,30(6) :1115 - 1123.
  • 6Steinbrink K, Graulich E, Kubsch S,et al. CD4+ and CD8 + anergic T cells induced by interleukin - 10 - treated human dendritic cells display antigen - specific suppressor activity. Blood, 2002,9991 (2) : 2468 - 2476.
  • 7Buja LM. Myocardial ischemia and reperfusion injury[J]. CardiovascPathol, 2005, 14(4): 170-175.
  • 8Ruiz Gines JA, Lopez Ongil S, Gonzalez Rubio M, et al. Reactive oxy-gen species induce proliferation of bovine aortic endothelialcells[J]. J Cardiovasc Pharmacol, 2000, 3S (1) : 109-113.
  • 9Jansen J, Hanks S, Thompson JM, et al. Transplantation of hematopoietic stem cells from the peripheral blood[J]. J Cell Mol Med, 2005, 9(1): 37-50.
  • 10Cavallaro AM, Lilleby K, Majolino I, et al. Three to six year follow-upof normal donors who received recombinant human granulocyte colony-stimulating factor [J]. Bone Marrow Transplant, 2000, 25(1): 85-89.

引证文献6

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部